ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 798

Development of Large Vessel Vasculitis Including Aortitis in a Patient with Deficiency of the IL-1 Receptor Antagonist (DIRA) Points to Converging Roles of IL-1 and TNF in Vascular Pathogenesis Recapitulating Findings from a Murine Model

Gina Montealegre Sanchez1, Adriana de Jesus 1, Jenna Wade 2, Katherine Townsend 1, Arianne Soldatos 3, Alessandra Brofferio 4, Peter C. Grayson 5, Ginger Janow 6 and Raphaela Goldbach-Mansky 1, 1Translational Autoinflammatory Disease Section/NIAID/NIH, Bethesda, 2Translational Autoinflammatory Diseases Section/NIAID/NIH, Bethesda, 3NIH/NINDS, Bethesda, 4NIH/NHLBI, Bethesda, 5National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD, 6Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center, NJ

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: DIRA and anti-TNF therapy, large vessel vasculitis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Sunday, November 10, 2019

Session Title: Pediatric Rheumatology – ePoster I: Basic Science, Biomarkers, & Sclerodermic Fever

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Deficiency of interleukin-1-receptor antagonist (DIRA) is a rare autoinflammatory disease caused by autosomal recessive loss of function mutations in IL1RN and characterized by early-onset generalized pustulosis, aseptic multifocal osteomyelitis, and elevation of acute-phase reactants. In a DIRA mouse model, aortitis can develop in a TNF-α dependent manner, no DIRA patients with large vessel vasculitis have previously been reported.

Methods: We performed clinical, genetic and radiographic evaluation of a patient with DIRA who developed an intra-cranial hemorrhage on anakinra treatment and had persistent low-grade elevation of acute phase reactants. We performed including whole exome sequencing and PET CT.

Results: A Puerto Rican patient previously reported with a homozygous 175-kb deletion and multiple comorbidities including severe bone deformities, developmental delay, generalized hypotonia at birth, pyoderma gangrenosum, developed a left intra-cranial hemorrhage at age 12. Follow-up work up of potential pathogenic causes revealed right-sided carotiditis and aortitis on PET CT images. Vascular findings were associated with carotid stenosis and an ascending aortic aneurism. Vascular abnormalities occurred while on optimal doses of anakinra (3.33 ±1.82 mg/kg/day) but persistently elevated inflammatory markers(CRP 5.41 ±3.08 mg/L and ESR 21.40 ±13.99 mm/hr). No other patient with DIRA was diagnosed with large vessel. vasculitis. While IL-1 receptor antagonist (Il-1ra) knock out (KO) murine models are prone to the development of vascular diseases, different genetic backgrounds modify vascular inflammation and injury. Il1ra KO on a C57BL/6J background is associated with intima damage and the development of atherosclerosis and Il1ra KO BALB/c mice develop aortitis that is responsive to TNF inhibition. Insights into the murine model suggested addition of TNF inhibitor after failure of increased doses of anakinra and steroids in achieving disease control. Acute phase reactants normalized after treatment with infliximab. Genetic analyses of rare variants that may contribute to the development af large vessel vasculitis are ongoing.

Conclusion: The development of large vessel vasculitis including carotitis and aortitis in a patient with DIRA who responds to combination therapy of IL-1 and TNF inhibition suggests a role of TNF in the development of large vessel vasculitis and may provide insights into pathways that may shed light on the pathogenesis of other forms of large vessel vasculitis. Strict monitoring of adverse events is required given the increased risk for opportunistic infections.

Funding for this study was provided in part by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health.


Disclosure: G. Montealegre Sanchez, None; A. de Jesus, None; J. Wade, None; K. Townsend, None; A. Soldatos, None; A. Brofferio, None; P. Grayson, None; G. Janow, None; R. Goldbach-Mansky, None.

To cite this abstract in AMA style:

Montealegre Sanchez G, de Jesus A, Wade J, Townsend K, Soldatos A, Brofferio A, Grayson P, Janow G, Goldbach-Mansky R. Development of Large Vessel Vasculitis Including Aortitis in a Patient with Deficiency of the IL-1 Receptor Antagonist (DIRA) Points to Converging Roles of IL-1 and TNF in Vascular Pathogenesis Recapitulating Findings from a Murine Model [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/development-of-large-vessel-vasculitis-including-aortitis-in-a-patient-with-deficiency-of-the-il-1-receptor-antagonist-dira-points-to-converging-roles-of-il-1-and-tnf-in-vascular-pathogenesis-recapi/. Accessed February 28, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-of-large-vessel-vasculitis-including-aortitis-in-a-patient-with-deficiency-of-the-il-1-receptor-antagonist-dira-points-to-converging-roles-of-il-1-and-tnf-in-vascular-pathogenesis-recapi/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.